explore -WSS

explore

author：fashion 2025-09-06 03:53:44 - browse：624

Amid the stunning rebuke Amgen suffered at the hands of the U.S. Food and Drug Administration this week lurk numerous questions. And one of them may be whether the company was fully forthcoming about a pricey lung cancer drug that is supposed to generate key revenue growth.

At issue is a trial that Amgen is relying upon to win final approval for Lumakras, which the FDA approved on a conditional basis in 2021. This process, known as accelerated approval, required the company to run a confirmatory study. But ahead of an advisory panel meeting on Thursday, the agency released documents showing its staff found “potential systemic bias” in the trial.

The disclosure throws into question the future of this drug, which has offered hope to patients for whom an effective treatment previously seemed out of reach. Some Wall Street analysts are now betting the FDA will ask Amgen to run yet another trial or maybe withdraw the drug altogether. Either way, the prognosticators are reworking their calculus for Amgen stock.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Fetal surgery at risk from Dobbs and new abortion restrictions

focus

explore

WSS

Rep. Raul Ruiz on the physician shortage and more

Will the market for weight loss drugs really reach $100 billion?

Researchers CRISPR chickens in bid to protect them from bird flu

Peter Marks talks Operation Warp Speed for Rare Diseases

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

What don’t we know about an Alzheimer’s drug side effect?

leisure time

explore

focus

Moonlake's readout produced a cash windfall. Risks remain

Takeaways from AdvaMed, the largest medical devices conference

Sports medicine is finally prioritizing gender equality

Diagnostic tests are hitting their mathematical limits

In age of alternative facts, a scholarly course on calling out crap

Life sciences deals on track to hit lowest point since 2017

Jerome Adams on the need for new antivirals for Covid

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

Cancer drug shortages should be causing more outrage

Cancer cells are shown to suck energy source from immune cells

leisure time

Mayo Clinic plans $5B tech

Diagnostic tests are hitting their mathematical limits

A fraught question for the kids of Alzheimer’s: Is it coming for us?

How should state employee insurance handle Wegovy?

A fraught question for the kids of Alzheimer’s: Is it coming for us?

U.K. Biobank has 500,000 peoples' genome sequences available

focus

explore

hotspot

focus